GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
136 articles on this topic
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
Compounded Tirzepatide Side Effects: What Changes?
Most side effects come from tirzepatide itself. Compounding can add a second layer of risk through concentration, measurement, added ingredients, sterility, and potency.
-
Semaglutide Before and After: An Honest Timeline
The first month is usually an adjustment period, month six is still part of the active curve, and a plateau often comes much later. Photos cannot show the treatment, timing, or follow-up behind a change.
-
Tirzepatide for Seniors: What New 2026 Data Show
Age 65 alone does not rule out tirzepatide. New 2026 research is reassuring, but adults over 75 remain underrepresented and the safest decision turns on muscle reserve, hydration, kidney health and other medicines.
-
FDA Telehealth Compounded Drugs: 5 Red Flags
FDA says telehealth sites must not present a compounded drug as a generic, a brand equivalent, or an agency-reviewed product. Here is what an honest prescription page should make clear.
-
Generic Semaglutide Exists—Just Not in the U.S.
Canada now has authorized semaglutide generics. The U.S. has only a tentative approval, while compounded semaglutide is another category altogether.
-
Orforglipron Is Approved: What Foundayo Changes
Orforglipron is now sold as Foundayo, a once-daily GLP-1 pill for weight management. It removes the fasting rules of oral semaglutide, but it does not replace every reason someone may choose an injection.
-
Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-
Tirzepatide Before and After: An Honest Timeline
Tirzepatide before and after photos can't tell you what caused a change. The trials give a more useful timeline: early appetite shifts, months of gradual change, and a later plateau that varies widely.
-
Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-
Tirzepatide and Blood Pressure: Does It Lower It?
Yes—blood pressure often falls during tirzepatide treatment, mostly alongside weight loss. That can be welcome, but it also means people taking blood-pressure medicine may need closer review if lightheadedness starts.
-
Tirzepatide and Gallbladder Risk: Small but Real
Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.
-
Tirzepatide and Menopause: What the Evidence Says
Menopause does not appear to stop tirzepatide from working for weight management. The useful question is whether it fits the whole health picture, including sleep, muscle, bone and any hormone therapy already in use.
-
Tirzepatide Psoriasis Data Don’t Make It a Treatment
New 52-week data found better skin and joint outcomes when branded tirzepatide was added to Taltz in adults with psoriatic disease and obesity. That supports treating two linked conditions together—not using tirzepatide alone for psoriasis.
-
Tirzepatide 3 Month Supply: What You Get
Three months usually means a series of monthly dose packages, not one vial kept open for 90 days. The prescription, storage dates, and billing period each answer a different part of the question.
-
What Is Cagrilintide? The Amylin Half of CagriSema
Cagrilintide is an experimental copy of the appetite hormone amylin, and the other half of Novo Nordisk's CagriSema. It is not approved, it is not sold here, and a US decision is expected before the end of 2026.
-
Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-
GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-
How to Choose a Tirzepatide Provider: 7 Checks
Most of the difference between a careful service and a careless one shows up before a vial ever arrives — in who reads your history, who makes the medicine, and whether anyone answers afterwards.
Page 2 of 7 · 136 articles